Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common cause of female infertility, affecting 5-10% of women of reproductive age. Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis. Therefore, we designed a present meta-analysis of randomized controlled trials to explore the effect of myo-inositol supplementation on anthropometric, metabolic, and endocrine outcomes in PCOS patients. Randomized controlled trials assessing the effectiveness of myo-inositol were identified in electronic databases like PubMed, Cochrane, Embase, MEDLINE, CINAHL, and AMED. Listed references and citations of related articles were also screened manually to identify additional studies. Research papers for which full-text copies were not available on scientific databases were procured from respective authors. Thereafter, data were extracted from included studies and analyzed using RevMan 5.3 of the Cochrane Collaboration. A total of 17 randomized controlled trials with 1083 PCOS patients were included in this meta-analysis. Among the 17 trials, 7 trials compared myo-inositol with folic acid, 8 trials compared myo-inositol with metformin, and 2 trials compared myo-inositol with oral contraceptives. No significant improvement in body mass index, waist-to-hip ratio, fasting insulin, fasting glucose, HOMA, LH, FSH, estradiol, sex hormone-binding globulin, dehydroepiandrosterone, and total testosterone levels were observed after myo-inositol treatment in PCOS patients except androstenedione and prolactin levels. Clinically significant improvement was not observed in anthropometric, metabolic, and endocrine outcomes after myo-inositol treatment in PCOS patients. However, heterogeneity between studies was high.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our findings are consistent with a recent meta-analysis by Jethaliya and colleagues (61) who examined the efficacy of MI against any comparator for anthropometric, metabolic, and endocrine outcomes in PCOS and included 17 RCTs.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [61]
In the citing paper
“Similar to our findings, they did not find any improvements in anthropometric (BMI, WHR), metabolic (fasting insulin, fasting glucose, HOMA-IR), or hormonal (luteinizing hormone, FSH, oestradiol, SHBG, DHEAS, and total testosterone levels) outcomes with the exception of androstenedione levels, which favored inositol (61).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [61]
Citations
Cites
3 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“We were unable to analyze parameters like free androgen index, glucose-insulin ratio, progesterone level, and also parameters for lipid profile, reproductive, and ovarian function in the present meta-analysis because these parameters were reported by only one or two RCTs, which were insufficient for conducting evaluat…”
Retracted- Retracted
Jamilian, H., Jamilian, M., Foroozanfard, F., Afshar Ebrahimi, F., Bahmani, F., & Asemi, Z. (2018) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2017.1383381 · Cited by 20
RetractedDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 2,916
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790 · cited 1×
“DCI mediates insulin-dependent androgen synthesis, whereas uptake of glucose and follicle-stimulating hormone (FSH) signaling is mediated by MI [19, 20].”
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 1×
“Along with this, long-term health consequences of PCOS are type 2 diabetes mellitus [2, 3], dyslipidemia [4], low-grade inflammation [5], endothelial dysfunction [6], and psychological distress [7, 8].”
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“Along with this, long-term health consequences of PCOS are type 2 diabetes mellitus [2, 3], dyslipidemia [4], low-grade inflammation [5], endothelial dysfunction [6], and psychological distress [7, 8].”
Palareti, G., Legnani, C., Cosmi, B., Antonucci, E., Erba, N., Poli, D., Testa, S., Tosetto, A., & the DULCIS (D‐dimer‐ULtrasonography in Combination Italian Study) Investigators (See Appendix) (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12426 · Cited by 902
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Low grade chronic inflammation in women with polycystic ovarian syndrome
Kelly, C. C. J., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. C., & Sattar, N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7580 · Cited by 640
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · cited 1×
“Pieces of evidence suggest that IR and resulting hyperinsulinemia are correlated with abnormal steroidogenesis of the ovary [12] and also contribute to the pathogenesis of anovulation and hyperandrogenism [11, 13].”
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · cited 1×
“It is well understood that abnormal neuroendocrine function like increased GnRH pulse frequency is responsible for alteration in ovarian folliculogenesis, steroidogenesis, and resulting excess androgen production in PCOS patients [58].”
Willis, D., Mason, H., Gilling-Smith, C., & Franks, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550768 · Cited by 371
Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis
Barry, J. A., Kuczmierczyk, A. R., & Hardiman, P. J. (2011) · Human Reproduction · doi:10.1093/humrep/der197 · Cited by 336
Tarkun, İ., Arslan, B. Ç., Cantürk, Z., Türemen, E., Şahı̇n, T., & Duman, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0751 · Cited by 296
O'Reilly, M. W., Taylor, A. E., Crabtree, N. J., Hughes, B. A., Capper, F., Crowley, R. K., Stewart, P. M., Tomlinson, J. W., & Arlt, W. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3399 · Cited by 283
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin
Pugeat, M., Crave, J. C., Elmidani, M., Nicolas, M. H., Garoscio-Cholet, M., Lejeune, H., Déchaud, H., & Tourniaire, J. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90310-2 · Cited by 215
Dokras, A., Clifton, S., Futterweit, W., & Wild, R. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.10.022 · Cited by 209 · cited 1×
“Along with this, long-term health consequences of PCOS are type 2 diabetes mellitus [2, 3], dyslipidemia [4], low-grade inflammation [5], endothelial dysfunction [6], and psychological distress [7, 8].”
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Dyslipidemia in women with polycystic ovary syndrome
Kim, J. J., & Choi, Y. M. (2013) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2013.56.3.137 · Cited by 190
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188
PCOS Forum: research in polycystic ovary syndrome today and tomorrow: Forum in PCOS research
Pasquali, R., Stener-Victorin, E., Yildiz, B. O., Duleba, A. J., Hoeger, K., Mason, H., Homburg, R., Hickey, T., Franks, S., Tapanainen, J. S., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03956.x · Cited by 185
Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome
Cascella, T., Palomba, S., De Sio, I., Manguso, F., Giallauria, F., De Simone, B., Tafuri, D., Lombardi, G., Colao, A., & Orio, F. (2007) · Human Reproduction · doi:10.1093/humrep/dem356 · Cited by 184
Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease
Bizzarri, M., Fuso, A., Dinicola, S., Cucina, A., & Bevilacqua, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1206887 · Cited by 183
(2009) · PubMed · Cited by 160
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154
Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151
Genazzani, A. D., Battaglia, C., Malavasi, B., Strucchi, C., Tortolani, F., & Gamba, O. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.05.020 · Cited by 141
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
Ciampelli, M., Fulghesu, A. M., Cucinelli, F., Pavone, V., Ronsisvalle, E., Guido, M., Caruso, A., & Lanzone, A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90028-8 · Cited by 132
Barber, T. M., Dimitriadis, G. K., Andreou, A., & Franks, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-262 · Cited by 117
Pundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A., & Thangaratinam, S. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14754 · Cited by 115 · cited 2×
“Numerous systematic reviews and meta-analysis have also been published, comparing MI with metformin [25, 26], oral contraceptives, DCI [27], and placebo [28, 29].”
Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality
Haring, R., Friedrich, N., Völzke, H., Vasan, R. S., Felix, S. B., Dörr, M., zu Schwabedissen, H. E. M., Nauck, M., & Wallaschofski, H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs233 · Cited by 112
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · cited 1×
“We were unable to analyze parameters like free androgen index, glucose-insulin ratio, progesterone level, and also parameters for lipid profile, reproductive, and ovarian function in the present meta-analysis because these parameters were reported by only one or two RCTs, which were insufficient for conducting evaluat…”
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100 · cited 1×
“Results of such studies suggest the improvement in IR, menstrual irregularities, acne score, and various endocrine as well as metabolic parameters [23].”
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94 · cited 2×
“On the contrary, other meta-analysis studies reported no significant improvement in endocrine parameters like testosterone level [28, 53].”
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome
Azziz, R., Ehrmann, D. A., Legro, R. S., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04914-2 · Cited by 91
The Association Between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis
Yang, H., Di, J., Pan, J., Yu, R., Teng, Y., Cai, Z., & Deng, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00263 · Cited by 91
Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89 · cited 1×
“Therefore, it is recommended for the treatment of PCOS [56].”
Regidor, P.-A., Schindler, A. E., Lesoine, B., & Druckman, R. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0067 · Cited by 74
Arentz, S., Smith, C. A., Abbott, J., & Bensoussan, A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2011-x · Cited by 66
Shokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63
Myo-Inositol in the Treatment of Teenagers Affected by PCOS
Pkhaladze, L., Barbakadze, L., & Kvashilava, N. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1473612 · Cited by 62
Zheng, X., Lin, D., Zhang, Y., Lin, Y., Song, J., Li, S., & Sun, Y. (2017) · Medicine · doi:10.1097/md.0000000000008842 · Cited by 62
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59
Current perspectives of insulin resistance and polycystic ovary syndrome
Pauli, J. M., Raja‐Khan, N., Wu, X., & Legro, R. S. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03460.x · Cited by 54
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 50
Georgopoulos, N. A., Papadakis, E. P., Armeni, A. K., Katsikis, I., Roupas, N. D., & Panidis, D. (2014) · HORMONES · doi:10.1007/bf03401335 · Cited by 40
Ozay, A. C., Emekci Ozay, O., Okyay, R. E., Cagliyan, E., Kume, T., & Gulekli, B. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3206872 · Cited by 34
Angik, R. (2015) · International Journal of Reproduction, Contraception, Obstetrics and Gynecology · doi:10.5455/2320-1770.ijrcog20150234 · Cited by 33
Pourghasem, S., Bazarganipour, F., Taghavi, S. A., & Kutenaee, M. A. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05064-5 · Cited by 28
Nehra, J., Kaushal, J., Singhal, S. R., & Ghalaut, V. S. (2017) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i4.16359 · Cited by 23 · cited 2×
“The worldwide prevalence of * Roshni Patel roshni.patel@kbiper.ac.in 1 Department of Pharmacology and Pharmacy Practice, K. B. Institute of Pharmaceutical Education and Research, Near Gh-6 circle, Sector-23, Gandhinagar 382023, Gujarat, India this heterogeneous disease is around 5–10% in reproductiveaged women [9].”
Bhide, P., Pundir, J., Gudi, A., Shah, A., Homburg, R., & Acharya, G. (2019) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.13625 · Cited by 22
Maria Concetta Musacchio, V. D. L. (2013) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000127 · Cited by 19
Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.05.041 · Cited by 11
Research works printed but not linked: 4
- Robert J, Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;9588:685–97.
- Kabel AM. Journal of pharmacological reports polycystic ovarian syndrome : insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. J Pharmacol Rep. 2016;1:1–5.
- Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35:198–206. https://doi.org/10.1080/09513590.2018.1540578. · DOI · Paper page
- Dona G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–10. https://doi.org/10.1530/EJE-11-0840. · DOI · Paper page
Cited by
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“…they did not find any improvements in anthropometric (BMI, WHR), metabolic (fasting insulin, fasting glucose, HOMA-IR), or hormonal (luteinizing hormone, FSH, oestradiol, SHBG, DHEAS, and total testosterone levels) outcomes with the exception of androstenedione levels, which favored inositol (61).”
BackgroundResultUnfer, V., Kandaraki, E., Pkhaladze, L., Roseff, S., Vazquez-Levin, M. H., Laganà, A. S., Chan, S. Y., Yap‐Garcia, M. I. M., Greene, N. D. E., Soulage, C. O., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100159 · Cited by 70
“…that inositol supplementation represents an effective therapeutic approach in women with PCOS, by improving metabolic and endocrine alterations, optimizing insulin and FSH signaling in the ovary, and reducing the presence of hyper-androgenism (Pkhaladze et al., 2021; Jethaliya et al., 2022).”
BackgroundFatima, K., Jamil, Z., Faheem, S., Adnan, A., Javaid, S. S., Naeem, H., Mohiuddin, N., Sajid, A., & Ochani, S. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03388-5 · Cited by 30
Skowrońska, M., Pawłowski, M., & Milewski, R. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196275 · Cited by 22
Lin, L., Chen, G., Qiao, X., Chen, Y., Deng, H., & Xu, L. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01576-0 · Cited by 22
Metadata
- Authors
- Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R.
- Corresponding author
- Patel, Roshni
- ORCID
- Patel, Roshni
- Venue
- Reproductive Sciences
- Published
- 2022-04-27
- Volume
- 29
- Issue
- 8
- Pages
- 2282-2298
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W4225100565
- Cited by
- 17
- References
- 59
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 3
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- myo-inositol, polycystic ovary syndrome, insulin resistance, insulin sensitivity, anthropometric outcomes, body mass index, waist-to-hip ratio, metabolic outcomes, endocrine outcomes, androstenedione, prolactin, sex hormone-binding globulin, testosterone, metformin, folic acid, oral contraceptives, female infertility
- MeSH terms
- Female, Folic Acid, Humans, Inositol, Insulin, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.